Tirzepatide vs Retatrutide
Tirzepatide vs Retatrutide: dual vs triple agonist. Effect size, side effects, and current availability.
The verdict
Same family, different reach: Tirzepatide is a dual agonist (GLP-1 + GIP), Retatrutide is a triple (it adds glucagon). The extra receptor is why Retatrutide's trial weight-loss numbers run higher. But Tirzepatide is FDA-approved and proven in the real world, while Retatrutide is still in trials. For anyone wanting an available, well-documented compound right now, Tirzepatide is the call. Retatrutide is the upgrade path if and when it clears approval.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Retatrutide is the newest weight-loss compound in development at Eli Lilly. It's a stronger cousin of Tirzepatide (Mounjaro / Zepbound) and pulls bigger weight loss in trials, often 20%+ of body weight. One injection per week. Side effects are real, especially in the first few weeks.
Which one should you pick?
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Pick Retatrutide if people plateaued on tirzepatide or users targeting >15% body weight loss.
Still torn between Tirzepatide and Retatrutide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.